Selecta Biosciences has been granted a patent for a method involving the administration of a composition comprising synthetic nanocarriers and immunosuppressants to induce immune suppressive effects and antigen-specific tolerogenic immune responses. The composition includes polymeric synthetic nanocarriers coupled with an immunosuppressant, such as rapamycin, and an antigen. The nanocarriers have specific size dimensions and the immunosuppressant load is between 2% and 25%. This method is useful for subjects requiring antigen-specific tolerance. GlobalData’s report on Selecta Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Selecta Biosciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Selecta Biosciences's grant share as of September 2023 was 20%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for a method of administering immunosuppressant nanocarriers with antigen
A recently granted patent (Publication Number: US11717569B2) describes a method for administering a composition to a subject in need of antigen-specific tolerance. The composition includes polymeric synthetic nanocarriers coupled with an immunosuppressant, specifically rapamycin or a rapamycin analog, and an antigen that can be presented by antigen-presenting cells (APCs). The immunosuppressant load on the nanocarriers is between 2% and 25% (weight/weight), and at least 75% of the nanocarriers have a minimum dimension greater than 110 nm and a maximum dimension equal to or less than 500 nm.
The method aims to induce a tolerogenic immune response specific to the APC-presentable antigen. It can be administered in an amount effective to achieve this response. The administration can follow a previously established protocol that has shown success in generating a tolerogenic immune response in test subjects. The method also includes providing or identifying the subject and assessing the generation of the tolerogenic immune response.
The method is particularly useful for subjects with autoimmune diseases, inflammatory diseases, allergies, organ or tissue rejection, graft versus host disease, or those who have undergone or are expected to undergo transplantation. It can also be used for subjects who have received or are receiving a therapeutic protein that has triggered an undesired immune response.
The composition can be administered through various routes such as intravenous, transmucosal, intraperitoneal, oral, subcutaneous, pulmonary, intranasal, intradermal, intramuscular, inhalation, intravenous, subcutaneous, or transmucosal administration.
The APC-presentable antigen can be coupled to the synthetic nanocarriers of the first population or the synthetic nanocarriers of a second population. The antigen can include MHC class I-restricted and/or MHC class II-restricted epitopes, lipids that bind to CD1d, therapeutic proteins or portions thereof, autoantigens, allergens, or antigens associated with autoimmune diseases, inflammatory diseases, allergies, organ or tissue rejection, or graft versus host disease.
The polymeric synthetic nanocarriers of the first population can comprise a non-methoxy-terminated, ethylene oxide and propylene oxide copolymer. They can also include polymers such as polyesters, polyethers, polyamino acids, polycarbonates, polyacetals, polyketals, polysaccharides, polyethyloxazoline, or polyethyleneimine.
The majority of the synthetic nanocarriers have dimensions that fall within 20% of the average minimum or maximum dimension, with at least 80% meeting this criterion. Higher percentages, such as 90% or 95%, can also be achieved. In some embodiments, the dimensions fall within 10% or even 5% of the average.
Overall, this patent describes a method for administering a composition that combines synthetic nanocarriers, an immunosuppressant, and an antigen to induce antigen-specific tolerance in subjects with various immune-related conditions.
To know more about GlobalData’s detailed insights on Selecta Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
